KA/EN
Register
Medicines reference
Search
Search
Active substance

Folic acid

Favourites

B vitamin. Registered in Georgia: 2 human medicines. Forms: coated tablet.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Folic acid
Dose Species Indication Route Frequency Source
5 mg per animal
off-label
 Dog Maintenance By mouth once daily for 1 month
MSD Vet Manual 2025
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Drugs Acting on the Blood or Blood-Forming Organs in Animals
MSD/Merck Veterinary Manual, 2025
2.5 mg per animal
off-label
 Cat Maintenance By mouth once daily for 1 month
MSD Vet Manual 2025
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Drugs Acting on the Blood or Blood-Forming Organs in Animals
MSD/Merck Veterinary Manual, 2025
Before use

Safety information

No sourced safety entry is currently shown. This does not mean the substance is risk-free.

Latin name
Folic acid
Georgian name
ფოლიუმის მჟავა
Authorisation status
Human medicine, cascade use
No veterinary authorisation was found in any register checked. Veterinary use is off-label, under the prescribing cascade.
Registered in Georgia
2 of 2 forms
Products
Benevron BF, Neo-Ferro-Folgamma
Human medicines in Georgia
Folfa, Folfull, Lompasar
Human medicines with this substance in the Georgian register of medicines (Ministry of Health), checked on 18 Oct 2026. They are human medicines, not veterinary products; strengths and forms differ.
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration2

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Benevron BF 20 gastro-resistant tablets, Coated tablet

human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Proposed oral use of the exact Benevron BF human gastro-resistant product for a diagnosed vitamin deficiency or adjunctive neurologic role
Not rateable
No numerical score assigned
vetman assessment

Benevron BF

20 gastro-resistant tablets, human medicine
Assessed clinical scopeDog · Proposed oral use of the exact Benevron BF human gastro-resistant product for a diagnosed vitamin deficiency or adjunctive neurologic role · By mouth
Care settingVeterinarian-directed use only after diagnosis and selection of a source-backed, deliverable regimen
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Yes, human · № რ-046262, რ-044386 · Verified on 15 Oct 2026 Off-label use
Not rateable

A numerical canine score cannot be assigned responsibly. AEM DV 25-00460 verifies the Azerbaijani gastro-resistant medicine, while the exact World Medicine Kazakhstan document describes the same name, composition and 20-tablet presentation as a food supplement. Neither source establishes a dog/cat regimen, veterinary PK, target-animal safety or outcomes; neither establishes a validated veterinary fraction.

Exact identity is documented, but the regulatory category differs by jurisdiction and no veterinary dose or validated tablet fraction is established.

Important safety and use flags

  • Use only for a defined deficiency or other explicit clinical rationale. A nonspecific neurologic sign, anorexia, fatigue or routine supplementation is not a diagnosis.
  • No dog or cat dose is established for this exact product. Do not restore a quarter-tablet practice or derive a fraction by arithmetic.
  • The exact presentation is gastro-resistant, but the audited primary documents do not establish scoring, equal-dose subdivision, whole-only administration or crushing instructions. Do not invent any of them.
  • AEM records a human medicine in Azerbaijan; the exact World Medicine Kazakhstan document calls the same name/composition/presentation a food supplement. Keep the jurisdiction-specific categories distinct.
  • Do not infer that all B vitamins are required because one deficiency is plausible. Ingredient or comparator evidence cannot validate this fixed high-dose ratio or transfer another product’s dose.
  • Each tablet contains 200 mg pyridoxine with four other vitamins. No product-specific dog/cat exposure threshold, safe duration or therapeutic margin is established.
  • High experimental pyridoxine exposure caused sensory-neuron injury in dogs. Those studies do not define a safe lower Benevron regimen, but they rule out assuming that water solubility makes chronic high-dose exposure harmless.
  • Review hypersensitivity to active ingredients and excipients. The exact product document lists sulfite and paraben excipients; target-animal tolerability is not established.
  • Review the full medication plan, especially levodopa without a peripheral decarboxylase inhibitor and other vitamin-containing products. Avoid unexamined cumulative exposure.
  • Set a diagnosis-specific response point and stop date. If response is absent, reassess diet, malabsorption, antagonists, primary disease and the actual deficient nutrient rather than continuing empirical B-complex treatment.
Assessment sources
  1. Benevron BF Azerbaijan register2025
  2. Benevron BF manufacturer document2026
  3. Small-animal nutrition2026
  4. Feline thiamine case2010
  5. Veterinary B12 comparator2025
  6. Canine oral pyridoxine toxicity1981
  7. Canine parenteral pyridoxine toxicity2008
Assessed: 23 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Cat Proposed oral use of the exact Benevron BF human gastro-resistant product for a diagnosed vitamin deficiency or adjunctive neurologic role
Not rateable
No numerical score assigned
vetman assessment

Benevron BF

20 gastro-resistant tablets, human medicine
Assessed clinical scopeCat · Proposed oral use of the exact Benevron BF human gastro-resistant product for a diagnosed vitamin deficiency or adjunctive neurologic role · By mouth
Care settingVeterinarian-directed use only after diagnosis and selection of a source-backed, deliverable regimen
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Yes, human · № რ-046262, რ-044386 · Verified on 15 Oct 2026 Off-label use
Not rateable

A numerical feline score cannot be assigned responsibly. AEM DV 25-00460 verifies the Azerbaijani gastro-resistant medicine, while the exact World Medicine Kazakhstan document describes the same name, composition and 20-tablet presentation as a food supplement. Neither source establishes a dog/cat regimen, veterinary PK, target-animal safety or outcomes; neither establishes a validated veterinary fraction.

Exact identity is documented, but the regulatory category differs by jurisdiction and no veterinary dose or validated tablet fraction is established.

Important safety and use flags

  • Use only for a defined deficiency or other explicit clinical rationale. A nonspecific neurologic sign, anorexia, fatigue or routine supplementation is not a diagnosis.
  • No dog or cat dose is established for this exact product. Do not restore a quarter-tablet practice or derive a fraction by arithmetic.
  • The exact presentation is gastro-resistant, but the audited primary documents do not establish scoring, equal-dose subdivision, whole-only administration or crushing instructions. Do not invent any of them.
  • AEM records a human medicine in Azerbaijan; the exact World Medicine Kazakhstan document calls the same name/composition/presentation a food supplement. Keep the jurisdiction-specific categories distinct.
  • Do not infer that all B vitamins are required because one deficiency is plausible. Ingredient or comparator evidence cannot validate this fixed high-dose ratio or transfer another product’s dose.
  • Each tablet contains 200 mg pyridoxine with four other vitamins. No product-specific dog/cat exposure threshold, safe duration or therapeutic margin is established.
  • High experimental pyridoxine exposure caused sensory-neuron injury in dogs. Those studies do not define a safe lower Benevron regimen, but they rule out assuming that water solubility makes chronic high-dose exposure harmless.
  • Review hypersensitivity to active ingredients and excipients. The exact product document lists sulfite and paraben excipients; target-animal tolerability is not established.
  • Review the full medication plan, especially levodopa without a peripheral decarboxylase inhibitor and other vitamin-containing products. Avoid unexamined cumulative exposure.
  • Set a diagnosis-specific response point and stop date. If response is absent, reassess diet, malabsorption, antagonists, primary disease and the actual deficient nutrient rather than continuing empirical B-complex treatment.
Assessment sources
  1. Benevron BF Azerbaijan register2025
  2. Benevron BF manufacturer document2026
  3. Small-animal nutrition2026
  4. Feline thiamine case2010
  5. Veterinary B12 comparator2025
  6. Canine oral pyridoxine toxicity1981
  7. Canine parenteral pyridoxine toxicity2008
Assessed: 23 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Thiamine250 mg Pyridoxine200 mg Riboflavin15 mg Folic acid0.5 mg Cyanocobalamin0.25 mg
Formulation Type
Coated tablet
Administration route
By mouth
Registration
Georgia Yes, human
In force until 08 Sep 2031
Human (Ministry of Health, RAMA)
№ რ-046262, რ-044386
Verified on: 15 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified No dog or cat dose was identified for this exact high-dose five-vitamin gastro-resistant product. The exact public documents contain human directions only and do not establish tablet subdivision, crushing, veterinary exposure or a treatment course.

Neo-Ferro-Folgamma 114 mg/0.8 mg, Coated tablet

gastro-resistant tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Oral iron replacement for laboratory-confirmed iron-deficiency anaemia after identifying and treating the underlying cause; fixed folate is not independently adequate folate replacement
5.6/10
Weak evidence support
vetman assessment

Neo-Ferro-Folgamma

114 mg/0.8 mg, gastro-resistant tablet, human medicine
Assessed clinical scopeDog · Oral iron replacement for laboratory-confirmed iron-deficiency anaemia after identifying and treating the underlying cause; fixed folate is not independently adequate folate replacement · By mouth
Care settingVeterinarian-directed off-label outpatient treatment with baseline diagnosis, interaction review, serial CBC/reticulocyte and iron-response monitoring, and immediate overdose safeguards.
vetman score 5.6/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, human · № რ-040151 · Verified on 15 Oct 2026 Off-label use

Traceable human iron/folate tablet with plausible canine iron-replacement value, but no exact veterinary study or defensible calculator dose. Use only after confirming iron deficiency; its folate component neither treats canine folate deficiency adequately nor supplies B12.

Regulatory and scientific credibility7.0/10

Exact current composition, manufacturer, dosage form and human regulatory identity are traceable, including Georgian human registration; none establishes veterinary approval, target-animal dose or efficacy.

Clinical efficacy5.5/10

Oral ferrous sulfate has an accepted canine hematinic role and the whole-tablet salt mass can nominally fit a class range, but no exact-product canine outcome/bioavailability study exists, the source does not resolve salt versus elemental mass, and the fixed folate dose is mismatched.

Safety and tolerability4.5/10

Known oral-iron GI intolerance and mucosal injury, clinically important interactions, diagnostic misuse and potentially severe elemental-iron overdose limit safety. Exact repeated-dose, reproductive and comorbidity safety in dogs is absent.

Clinical practicality5.5/10

Once-daily whole-tablet administration may be feasible in some dogs, but the unscored gastro-resistant tablet has no validated equal-subdivision or altered-administration instruction; exact dosing is unresolved, treatment is prolonged and serial laboratory monitoring plus interaction spacing are required.

Full-course cost-effectiveness-

A current Georgian exact-pack price and a validated exact-product veterinary course were not verified; cost is excluded from the denominator.

Important safety and use flags

  • Human gastro-resistant tablet. Georgian and European human registrations do not establish veterinary approval; all dog/cat use is off-label.
  • No exact-product dog/cat dose is established. Merck does not clarify whether its ferrous-sulfate milligrams are salt or elemental mass; do not create a calculator dose or copy a human regimen.
  • Each tablet provides 0.8 mg folic acid but no vitamin B12. This is below separately listed dog/cat folate regimens; do not titrate folate by adding tablets or use it as cobalamin replacement.
  • Confirm iron deficiency and investigate chronic blood loss, parasites, nutrition, malabsorption or other cause before treatment. Folate can improve haematology while unrecognised B12-related neurological injury continues.
  • The gastro-resistant tablet has no score or validated equal-division instruction. Do not assume splitting, crushing or chewing preserves dose accuracy or the enteric presentation; retained/chewed iron tablets can injure oral or oesophageal mucosa.
  • Monitor appetite, vomiting, diarrhoea/constipation, abdominal pain and dark stool, plus CBC/reticulocytes and iron indices. Non-response requires diagnostic reassessment, not automatic dose escalation.
  • Iron overdose is an emergency. Each tablet contains 36.77 mg elemental iron; calculate accidental exposure from elemental iron. More than 50 mg/kg generally warrants decontamination/GI protection and more than 80 mg/kg additional monitoring/treatment.
  • Avoid in iron overload, non-iron-deficiency anaemia and repeated transfusion without proven deficiency. Do not combine with parenteral iron or dimercaprol.
  • Review and appropriately separate antacids, calcium/magnesium, tetracyclines, fluoroquinolones, bisphosphonates, levothyroxine, penicillamine, zinc, cholestyramine and absorption-reducing foods; review anticonvulsants and folate antagonists.
  • Exact long-term, juvenile, pregnancy/lactation and comorbidity safety is not established. Store securely away from animals and children; delayed liver injury can follow an apparently improved overdose phase.
Assessment sources
  1. Neo-Ferro-Folgamma record2026
  2. Neo Ferro-Folgamma SPC2017
  3. Veterinary hematinics2025
  4. Veterinary iron toxicosis2025
  5. Canine iron indices2006
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Oral iron replacement for laboratory-confirmed iron-deficiency anaemia after identifying and treating the underlying cause; fixed folate is not independently adequate folate replacement
4.5/10
Weak evidence support
vetman assessment

Neo-Ferro-Folgamma

114 mg/0.8 mg, gastro-resistant tablet, human medicine
Assessed clinical scopeCat · Oral iron replacement for laboratory-confirmed iron-deficiency anaemia after identifying and treating the underlying cause; fixed folate is not independently adequate folate replacement · By mouth
Care settingVeterinarian-directed off-label outpatient treatment with baseline diagnosis, interaction review, serial CBC/reticulocyte and iron-response monitoring, and immediate overdose safeguards.
vetman score 4.5/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, human · № რ-040151 · Verified on 15 Oct 2026 Off-label use

Poorly fitted human fixed combination for cats: no exact feline study, no defensible calculator dose, and the whole tablet is above the nominal ferrous-sulfate range without a validated equal-subdivision instruction. Prefer a veterinarian-selected formulation that permits species-appropriate iron dosing.

Regulatory and scientific credibility7.0/10

Exact current composition, manufacturer, dosage form and human regulatory identity are traceable, including Georgian human registration; none establishes veterinary approval, target-animal dose or efficacy.

Clinical efficacy3.5/10

Iron replacement has biological rationale, but no exact-product feline efficacy or pharmacokinetic study exists; the 114 mg whole-tablet salt mass exceeds the nominal feline class range, cannot be accurately divided, and its fixed folate dose is mismatched.

Safety and tolerability4.0/10

The narrow whole-tablet fit adds to oral-iron GI/mucosal toxicity, interaction and severe overdose risks. Exact feline repeated-dose, reproductive and common-comorbidity safety is absent.

Clinical practicality3.0/10

The unscored gastro-resistant tablet has no validated equal-subdivision or altered-administration instruction and its whole-unit strength poorly fits the nominal feline range; prolonged administration, interaction spacing and serial laboratory monitoring further reduce practicality.

Full-course cost-effectiveness-

A current Georgian exact-pack price and a validated exact-product veterinary course were not verified; cost is excluded from the denominator.

Important safety and use flags

  • Human gastro-resistant tablet. Georgian and European human registrations do not establish veterinary approval; all dog/cat use is off-label.
  • No exact-product dog/cat dose is established. Merck does not clarify whether its ferrous-sulfate milligrams are salt or elemental mass; do not create a calculator dose or copy a human regimen.
  • Each tablet provides 0.8 mg folic acid but no vitamin B12. This is below separately listed dog/cat folate regimens; do not titrate folate by adding tablets or use it as cobalamin replacement.
  • Confirm iron deficiency and investigate chronic blood loss, parasites, nutrition, malabsorption or other cause before treatment. Folate can improve haematology while unrecognised B12-related neurological injury continues.
  • The gastro-resistant tablet has no score or validated equal-division instruction. Do not assume splitting, crushing or chewing preserves dose accuracy or the enteric presentation; retained/chewed iron tablets can injure oral or oesophageal mucosa.
  • Monitor appetite, vomiting, diarrhoea/constipation, abdominal pain and dark stool, plus CBC/reticulocytes and iron indices. Non-response requires diagnostic reassessment, not automatic dose escalation.
  • Iron overdose is an emergency. Each tablet contains 36.77 mg elemental iron; calculate accidental exposure from elemental iron. More than 50 mg/kg generally warrants decontamination/GI protection and more than 80 mg/kg additional monitoring/treatment.
  • Avoid in iron overload, non-iron-deficiency anaemia and repeated transfusion without proven deficiency. Do not combine with parenteral iron or dimercaprol.
  • Review and appropriately separate antacids, calcium/magnesium, tetracyclines, fluoroquinolones, bisphosphonates, levothyroxine, penicillamine, zinc, cholestyramine and absorption-reducing foods; review anticonvulsants and folate antagonists.
  • Exact long-term, juvenile, pregnancy/lactation and comorbidity safety is not established. Store securely away from animals and children; delayed liver injury can follow an apparently improved overdose phase.
Assessment sources
  1. Neo-Ferro-Folgamma record2026
  2. Neo Ferro-Folgamma SPC2017
  3. Veterinary hematinics2025
  4. Veterinary iron toxicosis2025
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Ferrous sulfate114 mg Folic acid0.8 mg
Formulation Type
Coated tablet
Administration route
By mouth
Manufacturer
Wörwag Pharma GmbH & Co. KG · Germany
Registration
Georgia Yes, human
In force until 06 Feb 2029
Human (Ministry of Health, RAMA)
№ რ-040151
Verified on: 15 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Each tablet contains dried ferrous sulfate 114 mg, equivalent to elemental iron 36.77 mg, plus folic acid 0.8 mg. No exact-product dog or cat dose is established. Merck lists ferrous sulfate 100–300 mg/day for dogs and 50–100 mg/day for cats but does not clarify salt versus elemental mass; the 114 mg gastro-resistant tablet has no score or equal-division instruction and exceeds the nominal feline range. Merck folic-acid regimens (dog 5 mg/day; cat 2.5 mg/day for one month) are not matched by this 0.8 mg fixed combination. Do not create a calculator dose or assume that splitting, crushing or chewing preserves dose accuracy and the gastro-resistant presentation.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 18 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗